ETOP IBCSG Partners Foundation
ETOP IBCSG Partners Foundation is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for ETOP IBCSG Partners Foundation?
The 2026-10-09 snapshot links ETOP IBCSG Partners Foundation to 4 distinct CTIS trials. Recorded services include Clinical monitoring, Project management, site activation, management and contracting, Site activation, management and contracting. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for ETOP IBCSG Partners Foundation?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to ETOP IBCSG Partners Foundation conducted?
The linked trials record locations in 15 countries, including Belgium, Germany, Spain, France, Italy. These are trial locations, not confirmed office locations or countries where ETOP IBCSG Partners Foundation delivered services.
What can this page tell me about ETOP IBCSG Partners Foundation's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under ETOP IBCSG Partners Foundation. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ETOP IBCSG Partners Foundation